Mammal female reproductive system

Loyal's Natural Wellness Products for Women Designed to Restore Balance to the Whole Body and Elevate Self Care, Now Available at Target

Retrieved on:

Friday, July 9, 2021

Health sciences, Pharmacology, Dosage forms, Medical specialties, Feminine hygiene, Gynaecology, Women's health, Mammal female reproductive system, Vagina, Pantyliner, Cream, Suppository

All of Loyal's products, including suppositories, mists, creams, supplements, applicators and pH test strips will be carried by one of the largest retailers in the world.

Key Points:

All of Loyal's products, including suppositories, mists, creams, supplements, applicators and pH test strips will be carried by one of the largest retailers in the world.
"We're thrilled that loyal's partnership with Target will empower women with the natural solutions they need for whole body love, while deconstructing the cultural shame surrounding feminine hygiene products," said Alex Stefanowitz, Director of Retail Sales at Loyal.
The Light Sleeper panty liner is pH balancing bamboo charcoal-infused layer designed to absorb discharge and maintain a balanced vaginal environment.
What started as a supplement company quickly became a passion project pivoting to natural wellness products after observing the current state of general vaginal health.

ObsEva to Present Ebopiprant (OBE022) Data at the Society for Reproductive Investigation 68th Annual Meeting

Retrieved on:

Friday, July 2, 2021

Anatomy, Midwifery, Obstetrics, Human reproduction, Mammal female reproductive system, Torso, Human female reproductive system, Women's health, Rupture of membranes, Cervix, Uterine contraction, Indometacin

PGF2 is believed to induce contractions of the myometrium and also upregulate enzymes causing cervix dilation and membrane rupture.

Key Points:

PGF2 is believed to induce contractions of the myometrium and also upregulate enzymes causing cervix dilation and membrane rupture.
In nonclinical studies, ObsEva has observed that ebopiprant markedly reduces spontaneous and induced uterine contractions in pregnant rats without causing the fetal side effects seen with non-specific prostaglandin inhibitors such as indomethacin.
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve womens reproductive health and pregnancy.
These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements.

SCYNEXIS Confirms that BREXAFEMME® (ibrexafungerp tablets) Qualifies for 10 Years of Regulatory Exclusivity for Vaginal Yeast Infections

Retrieved on:

Wednesday, June 9, 2021

Vagina, Branches of biology, Medical specialties, Mammal female reproductive system, Women's health, Gynaecology, Bacterial vaginosis, Human female reproductive system, Candidiasis, Vaginal discharge, Vaginitis, Vaginal yeast infection

This exclusivity will be added to any other applicable exclusivity periods, such as the five years of new chemical entity (NCE) exclusivity, for a combined ten-year period of regulatory exclusivity.

Key Points:

This exclusivity will be added to any other applicable exclusivity periods, such as the five years of new chemical entity (NCE) exclusivity, for a combined ten-year period of regulatory exclusivity.
We will also continue to work hard to fully leverage this regulatory exclusivity and our long patent protection to advance our pipeline of ibrexafungerp indications.
VVC, commonly known as a vaginal yeast infection due to Candida, is the second most common cause of vaginitis.
Typical VVC symptoms include pruritus, vaginal soreness, irritation, excoriation of vaginal mucosa and abnormal vaginal discharge.

PDS Biotech Announces Release of Interim Data for PDS0101 in NCI-Led Phase 2 Clinical Study in Oral Presentation at ASCO 2021 Annual Meeting

Retrieved on:

Tuesday, June 8, 2021

Cancer, Clinical medicine, Medicine, Papillomavirus, Infectious causes of cancer, Human female reproductive system, Mammal female reproductive system, Gynaecological cancer, Human papillomavirus infection, Vulvar cancer, Immunotherapy, Vagina

An additional four (4) HPV16-positive patients who are checkpoint inhibitor refractory whose data became available after the abstract submission.

Key Points:

An additional four (4) HPV16-positive patients who are checkpoint inhibitor refractory whose data became available after the abstract submission.
Most types of HPV-related cancers (anal, cervical, head and neck, vaginal and vulvar cancers) were represented among the study subjects.
The company is hosting a conference call tomorrow morning at 8:00 am ET to discuss the data presented at ASCO.
The companys lead investigational cancer immunotherapy product PDS0101 is currently in Phase 2 clinical studies in HPV-associated cancers.

Fertility Focus Announces Launch of OvuFirst Skin-Worn Sensor to Add Support for Women Starting Out on Their Journey to Pregnancy

Retrieved on:

Monday, June 7, 2021

Mammal female reproductive system, Reproduction, Human reproduction, Fertility awareness, Women's health, Gynaecology, Human female reproductive system, Vagina, OvuSense, Female mammals, Fertility testing, Fertility

The OvuSense App then uses this information to provide women with a full 8-day fertile window at the start of their next cycle.

Key Points:

The OvuSense App then uses this information to provide women with a full 8-day fertile window at the start of their next cycle.
In a side-by-side study volunteers wore the OvuCore vaginal sensor and OvuFirst skin sensor overnight for several cycles.
OvuFirst provided me with a non-invasive way to collect data and see trends to better understand my personal health.
To learn more about the OvuSense fertility monitoring family, visit ovusense.com .

Cliterate the world! First International Clitoris Summit, May 22, 2021

Retrieved on:

Friday, May 7, 2021

Mammal female reproductive system, Clitoris, Women's health

b'SAN DIEGO, May 7, 2021 /PRNewswire/ --An all new cliteracy organization Clitoris.io is launching its first International Clitoris Summit on May 22, 2021, featuring 18 renowned speakers whose pioneer work in medicine, sexology, arts, and activism has contributed to giving the clitoris the voice it deserves.\n"Our endeavour is to literally \'cliterate\' the world!"

Key Points:

b'SAN DIEGO, May 7, 2021 /PRNewswire/ --An all new cliteracy organization Clitoris.io is launching its first International Clitoris Summit on May 22, 2021, featuring 18 renowned speakers whose pioneer work in medicine, sexology, arts, and activism has contributed to giving the clitoris the voice it deserves.\n"Our endeavour is to literally \'cliterate\' the world!"
says Dr. Denisa Rensen, Clitoris.io spokesperson.
"The physical structure and function of the clitoris is still relatively unknown to most, this is a symptom of a much wider gender bias in medicine and culture.
Our goal is to inform, and to celebrate the only organ in the human body whose exclusive function is pleasure.

Global Vaginal Laxity Market (2021 to 2025) - Featuring Viveve Medical, Almirall, Hologic and Fotona Among Others - ResearchAndMarkets.com

Retrieved on:

Wednesday, May 5, 2021

General Health, Pharmaceutical, Health, Medical devices, Women's health, Human female reproductive system, Human reproduction, Anatomy, Gynaecology, Mammal female reproductive system, Vagina, Female mammals, Branches of biology

b'A wide number of treatments are available for vaginal laxity, which help women to regain their shape post child birth.

Key Points:

b'A wide number of treatments are available for vaginal laxity, which help women to regain their shape post child birth.
Some of the popular treatments for vaginal laxity are: kegel exercise, vaginal cones, tightening creams, vagina rejuvenation and reconstructive surgery.\nThe global vaginal laxity market has shown rising trends over the past few years and is anticipated to grow at a significant growth rate over the forecasted period i.e.
Drivers that are and would support the growth of the market are multiple normal delivery under proper attendant, application of forceps during childbirth, etc.\nThe market is expected to grow on the back of developing technology, emergence of genital aesthetics, etc.
However, the market is facing some challenges such as aftereffects associated with vaginal tightening surgery, high surgery cost, etc.\n'

Lauren Streicher, OBGYN and Menopause Expert, Releases “Slip Sliding Away,” a Guide to Tackling Menopause Symptoms

Retrieved on:

Tuesday, April 20, 2021

Yet, 80% of menopausal women experience symptoms such as hot flashes, vaginal dryness, weight gain, hair loss, brain fog, and insomnia, that impede their ability to think, sleep, work, and function sexually.

Key Points:

Yet, 80% of menopausal women experience symptoms such as hot flashes, vaginal dryness, weight gain, hair loss, brain fog, and insomnia, that impede their ability to think, sleep, work, and function sexually.
These women are turning to doctors for answers to combat their symptoms, but all too often are not offered solutions.\nEnter Slip Sliding Away: Turning Back the Clock on Your Vagina \xe2\x80\x93 gynecologist and best-selling author Lauren Streicher\xe2\x80\x99s latest resource that every woman needs.
This solution-driven guide addresses hormonal and non-hormonal options to alleviate vulvar, vaginal, and urinary symptoms as a result from a lack of estrogen that affects 60-70% of women over the age of 50.
Find more information about her practice and books on her website: https://www.drstreicher.com .\nSlip Sliding Away is now available for digital pre-sale; paperback and audio options will be available soon.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210420005233/en/\n'

SCYNEXIS and Amplity Health Announce Agreement to Support the Anticipated U.S. Commercialization of BrexafemmeTM (Ibrexafungerp) for Vaginal Yeast Infections

Retrieved on:

Tuesday, February 23, 2021

Articles, Animal diseases, Branches of biology, Vagina, Women's health, Gynaecology, Human female reproductive system, Mammal female reproductive system, Candidiasis, Blockbuster LLC, Team

Amplity, a leading global contract commercialization organization, specializes in designing, implementing, and managing customer facing and inside sales, service, medical and clinical teams.

Key Points:

Amplity, a leading global contract commercialization organization, specializes in designing, implementing, and managing customer facing and inside sales, service, medical and clinical teams.
We look forward to working with an Amplity womens health sales force and payer account management team fully dedicated to help realize Brexafemmes blockbuster potential.
Amplity has the potential to earn a performance-based success fee in the 2023-2025 time frame by exceeding certain revenue targets.
These patients and their doctors are eager for a new and differentiated alternative to treat vaginal yeast infections.

Female-Founded and Owned, First-to-Market Women’s Health Company pH-D® Feminine Health Announces Revenues Doubled to $12MM in 2020, Will More Than Double Again in 2021

Retrieved on:

Thursday, February 4, 2021

The company successfully doubled its sales from 2019 to 2020, reaching $12MM in total sales for last year.

Key Points:

The company successfully doubled its sales from 2019 to 2020, reaching $12MM in total sales for last year.
Additionally, pH-D Feminine Health quadrupled its distribution in brick and mortar stores to more than 25,000 locations in 2020.
This is especially important for women who have limited access to care nationwide, said Deeannah Seymour, Founder of pH-D Feminine Health.
pH-D Feminine Health, a privately held, women-owned and women-run company, worked with physicians to develop the number one doctor-recommended boric acid vaginal suppository.